医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BIA Separations Signs Two New Distribution Agreements Extending Coverage in Asia Pacific

2020年07月08日 PM06:06
このエントリーをはてなブックマークに追加


 

AJDOVŠČINA, Slovenia

BIA Separations, a leading bio-chromatography development and manufacturing company, today announced it has signed agreements with Bioscience companies, GeneX India Biosciences Pvt. Ltd. (GeneX India) and IT Technologies Pte. Ltd. (IT Tech). Both Companies will act as sole distributors of BIA Separations’ products and services across their respective regions of India, and Singapore and Malaysia.

BIA Separations provides research and method development services for the purification of large and complex biomolecules including those with therapeutic applications. Through the agreements, both distributors will provide academic researchers, CMOs and biopharmaceutical companies access to BIA Separations’ proprietary CIMac™ analytical and CIMmultus™ preparative purification technologies for cell and gene therapies, including viral vectors, nucleic acids, phages, and exosomes.

Ingo S. Nagler, Business Development Officer, BIA Separations commented:We are delighted to have GeneX India and IT Tech on board and look forward to jointly providing researchers and process developers across Asia with our state-of-the-art bioprocessing technologies and services, to enable the accelerated development of cell and gene based medicines.”

Felix Paul, Managing Director GeneX India Biosciences added:GeneX is committed to bringing the highest quality products to the market, with dedicated local customer service and support. The agreement with BIA Separations supports this mission, and we are very proud to be working with the team to ensure its leading purification technologies and expertise are available to research and bioproduction customers throughout India.”

Danapalan Arumugam, Managing Director at IT Tech said:IT Tech has been operating in Singapore and Malaysia since 1991, supporting customers in the field of chromatography across pharmaceuticals, food, chemicals, flavours and fragrances, through to petroleum. Cell and gene therapy is still at an early stage here, and therefore this is an exciting time to be signing a partnership with BIA Separations, enabling us to offer the Company’s products and services across research in this high-potential field.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005380/en/

CONTACT

Media contact

Sarah Jeffery

E: sarah.jeffery@zymecommunications.com

T: +44 (0)7771 730 919

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作